首页> 美国卫生研究院文献>Neurology and Therapy >Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)

【2h】

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)

机译：非洲人复发-多发性硬化症患者中Alemtuzumab的疗效和安全性：CARE-MS I和II的8年随访（TOPAZ研究）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The online version of this article (10.1007/s40120-019-00159-2) contains supplementary material, which is available to authorized users.

机译：本文的在线版本（10.1007 / s40120-019-00159-2）包含补充材料，可供授权用户使用。

著录项

期刊名称 Neurology and Therapy
作者
Annette F. Okai; Lilyana Amezcua; Regina R. Berkovich; Angel R. Chinea; Keith R. Edwards; Brian Steingo; Aljoeson Walker; Alan K. Jacobs; Nadia Daizadeh; Mitzi J. Williams; the CARE-MS I; CARE-MS II; CAMMS03409; and TOPAZ Investigators;
展开▼
作者单位

展开▼
年(卷),期 2019(8),2
年度 2019
页码 -1
总页数 15
原文格式 PDF
正文语种
中图分类神经科学;
关键词
African descent; Alemtuzumab; Disease-modifying therapy; Multiple sclerosis;

机译：非洲人后裔;阿仑单抗;疾病改良疗法;多发性硬化症;

相似文献

外文文献
中文文献
专利

1. Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients: 8-year follow-up of CARE-MS II (Topaz Study) [J] . Navas Carlos, Singer Barry A., Alroughani Raed, Multiple sclerosis: clinical and laboratory research . 2019,第1期

机译：Alemtuzumab在RRMS患者中提高了临床和MRI疾病活动结果，包括脑体积损失的放缓：Care-MS II（Topaz研究）的8年后续行动
2. Efficacy and Safety of Alemtuzumab in Patients With Relapsing-Remitting MS Who Relapsed on Prior Therapy: Four-Year Follow-up of the CARE-MS II Study [J] . Vucic S., Coles A. J., Arnold D. L., Multiple sclerosis: clinical and laboratory research . 2015,第6期

机译：Alemtuzumab在先前治疗后复发的复发缓解型MS患者中的疗效和安全性：CARE-MS II研究的四年随访
3. Patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy demonstrate durable improvements in clinical outcomes with alemtuzumab-5-year follow-up of CARE-MS II [J] . Alroughani Raed, Al Jumah Mohamed, Arnold Douglas L., Multiple sclerosis: clinical and laboratory research . 2016,第6期

机译：活动性缓解型多发性硬化症患者以及对先前治疗反应不足的患者通过Alemtuzumab对CARE-MS II进行了5年的随访，证明了其临床疗效的持久改善
4. Efficacy Analysis of Preservative-Free Tafluprost and Timolol in Open-Angle Glaucoma and OHT Patients in a Phase-III Study [C] . GrundenJ., Lupinacci R. International Symposium on Ocular Pharmacology and Therapeutics . 2013

机译：在第三阶段研究中，在开放角度荧光眼和OHT患者中无防腐型TaFluprost和蒂莫尔的疗效分析
5. An investigation of early relapsing-remitting multiple sclerosis patients using diffusion tensor imaging and spectroscopy. [D] . Zaini, Wan Hazlin. 2013

机译：使用扩散张量成像和光谱法对早期复发缓解型多发性硬化症患者进行调查。
6. Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis [O] . Rafael Arroyo, Denise P Bury, Jennifer D Guo, -1

机译：Alemtuzumab对6岁以上有效期的健康相关生活质量的影响 - 延长多发性硬化
7. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study [O] . Tjalf Ziemssen, Ann D. Bass, Regina Berkovich, 2020

机译：Alemtuzumab在高活跃疾病患者中通过9年通过9年的疗效和安全性：POSE-MS I和II患者在TOPAZ推广研究中的疗效分析

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)

摘要

著录项

相似文献

相关主题

期刊订阅